GlassScriptPhysician profile
Laura Ann Cure
NPI 1225746878
$5,180.39
in general payments reported to CMS, 2019-2025
33 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $574 · 2024: $2,208 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,180.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.25 | 2023-2025 | |
| Novo Nordisk INC | $833.33 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $538.61 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $419.20 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $368.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $290.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $202.33 | 2024-2025 | Gemtesa |
| Amgen INC. | $179.48 | 2023-2025 | Evenity, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.16 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $139.93 | 2024-2025 | Auvelity |
| Pfizer INC. | $125.34 | 2023-2025 | |
| Astellas Pharma US INC | $110.46 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.96 | 2023-2025 | Jardiance |
| Lundbeck LLC | $89.72 | 2024-2025 | Rexulti |
| Dexcom, INC. | $86.42 | 2023-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $63.41 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $61.11 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $53.73 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $48.29 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $43.61 | 2023-2025 | |
| Optinose US, INC. | $34.62 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $27.89 | 2025 | Neffy |
| Vertex Pharmaceuticals Incorporated | $25.28 | 2025 | |
| Abbott Laboratories | $23.43 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $21.02 | 2024 | Xarelto |
| Seqirus USA INC | $19.29 | 2024 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $18.97 | 2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2025 | Eliquis |
| Idorsia Pharmaceuticals US INC | $17.42 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $17.16 | 2023 | Seglentis, Livalo |
| Biogen, INC. | $16.94 | 2025 | Skyclarys |
| Esperion Therapeutics, INC. | $16.74 | 2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $13.81 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.